Agarwal Mugdha, Alam Mohammad Rizwan, Haider Mohd Kabir, Malik Md Zubair, Kim Dae-Kwang
Department of Biotechnology, Jaypee Institute of Information Technology, Noida 201309, India.
Department of Medical Genetics, School of Medicine, Keimyung University, Daegu 42601, Korea.
Nanomaterials (Basel). 2020 Dec 29;11(1):59. doi: 10.3390/nano11010059.
Alzheimer's disease (AD), a progressively fatal neurodegenerative disorder, is the most prominent form of dementia found today. Patients suffering from Alzheimer's begin to show the signs and symptoms, like decline in memory and cognition, long after the cellular damage has been initiated in their brain. There are several hypothesis for the neurodegeneration process; however, the lack of availability of in vivo models makes the recapitulation of AD in humans impossible. Moreover, the drugs currently available in the market serve to alleviate the symptoms and there is no cure for the disease. There have been two major hurdles in the process of finding the same-the inefficiency in cracking the complexity of the disease pathogenesis and the inefficiency in delivery of drugs targeted for AD. This review discusses the different drugs that have been designed over the recent years and the drug delivery options in the field of nanotechnology that have been found most feasible in surpassing the blood-brain barrier (BBB) and reaching the brain.
阿尔茨海默病(AD)是一种进行性致命的神经退行性疾病,是当今发现的最突出的痴呆形式。患有阿尔茨海默病的患者在其大脑开始出现细胞损伤很久之后,才开始表现出记忆力和认知能力下降等症状和体征。关于神经退行性变过程有几种假说;然而,缺乏体内模型使得在人类中重现阿尔茨海默病变得不可能。此外,目前市场上可用的药物只能缓解症状,这种疾病无法治愈。在寻找治愈方法的过程中存在两个主要障碍——破解疾病发病机制复杂性的效率低下以及针对阿尔茨海默病的药物递送效率低下。这篇综述讨论了近年来设计的不同药物以及纳米技术领域中在跨越血脑屏障(BBB)并到达大脑方面最可行的药物递送选择。